Bionaturis is a clinical-stage company that codevelops a new generation of biopharmaceutical products to hit unmet medical needs. Bionaturis´ pipeline is focused on orphan diseases and cutting-edge solutions for veterinarian applications.
BNT001:
Biobetter of recombinant human glucocerebrosidase for Gaucher disease. Lead optimization. Non-clinical studies Q3 2012
BNT004:
Intranasal recombinant vaccine for nematodes in livestock. Efficacy, effectiveness, and toxicity tested in both rodents and lambs trials. Ready to out-licensing
BNT005:
Canine visceral leishmaniasis recombinant prophylactic and therapeutic vaccine. Efficacy and toxicity tested in rodent challenges.
Bionaturis has on-going initiatives on state-of-the-art solutions for fish oral immunization, based on its proprietary patented formulations: FLYPIDs and FLYTE. Our team adapts early-stage biological drug leads, many of them obtained from academia, to the market specific requirements dictated by large pharmaceutical and veterinarian corporations.